Scienture's Arbli losartan oral suspension gains access to over 100 million covered lives through national commercial and ...

Scienture has commenced selling Arbli, the first FDA-approved ready-to-use liquid losartan formulation. ・The U.S. losartan market is worth about $256 million annually, offering strong growth potential ...

The MarketWatch News Department was not involved in the creation of this content. Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to ...

Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned ...

Scienture Holdings, Inc. (NASDAQ:SCNX) on Tuesday announced that it has formalized a commercial Pharmacy Benefit Manager (PBM) led Group Purchasing Organization (GPO) rebate agreement, advancing the ...

Represents potential penetration into ~ 20% of the U.S. institutional market, while broadening access across long-term care and outpatient facilities U.S. losartan market totals $256M annually with ...

An 8-week, multicenter, double-blind, randomized, parallel-group, forced-titration study was conducted to evaluate the antihypertensive efficacy of candesartan vs. losartan in 654 hypertensive ...

U.S. losartan market totals $256M annually with 71M prescriptions, creating a significant opportunity for Arbli ™ as the first FDA-approved ready-to-use oral suspension “This represents a paradigm ...